Education
About Us
Working with TipRanks
Follow Us
Reviva Pharmaceuticals Holdings (RVPH)
NASDAQ:RVPH
RVPH Stock Chart & Stats
$0.53
-$0.09(-4.50%)
At close: 4:00 PM EST
$0.53
-$0.09(-4.50%)
Day’s Range― - ―
52-Week Range$0.25 - $4.28
Previous CloseN/A
Volume1.63M
Average Volume (3M)14.40M
Market Cap
$53.27M
Enterprise Value$8.75M
Total Cash (Recent Filing)$10.36M
Total Debt (Recent Filing)$113.25K
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Mar 23, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding96,337,120
10 Day Avg. Volume22,198,486
30 Day Avg. Volume14,401,288
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)73.84
Price to Sales (P/S)0.00
P/FCF Ratio-1.79
Enterprise Value/Market Cap0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.47
Forecast
1Y Price Target
$5.14Price Target Upside869.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StabilityReviva announced an equity financing of $9M in gross proceeds raised through the issuance of shares of common stock, with additional funds raised from warrant exercises, extending their financial runway.
Regulatory AdvancementsThe upcoming pre-NDA meeting with the FDA will clarify the regulatory path for brilaroxazine in schizophrenia and determine whether an additional P3 study will be required. A favorable outcome could position Reviva for an NDA submission based on positive P2, P3 (RECOVER-1), 1-year open label extension study, and pharmacology study data.
Research And DevelopmentBrilaroxazine is scheduled to present late-breaking poster on anti-inflammatory biomarker data at the Society for Neuroscience Annual Meeting, which could raise awareness of the company's advancements in treating schizophrenia.
Bears Say
Development DelaysRisks include inability to complete pivotal development of brilaroxazine in schizophrenia in a timely manner.
Financial PerformanceReviva reported 2Q25 results with a net loss of ($6.1M) and ended the period with $10.4M, indicating potential financial challenges.
Market ValuationThe analyst has lowered the 12-month price target to $2.00 from $5.00, factoring in dilution and financial challenges.
Reviva Pharmaceuticals Holdings News
RVPH FAQ
What was Reviva Pharmaceuticals Holdings’s price range in the past 12 months?
Reviva Pharmaceuticals Holdings lowest stock price was $0.25 and its highest was $4.28 in the past 12 months.
What is Reviva Pharmaceuticals Holdings’s market cap?
Reviva Pharmaceuticals Holdings’s market cap is $53.27M.
When is Reviva Pharmaceuticals Holdings’s upcoming earnings report date?
Reviva Pharmaceuticals Holdings’s upcoming earnings report date is Mar 23, 2026 which is in 124 days.
How were Reviva Pharmaceuticals Holdings’s earnings last quarter?
Reviva Pharmaceuticals Holdings released its earnings results on Nov 13, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.095 by $0.035.
Is Reviva Pharmaceuticals Holdings overvalued?
According to Wall Street analysts Reviva Pharmaceuticals Holdings’s price is currently Undervalued.
Does Reviva Pharmaceuticals Holdings pay dividends?
Reviva Pharmaceuticals Holdings does not currently pay dividends.
What is Reviva Pharmaceuticals Holdings’s EPS estimate?
Reviva Pharmaceuticals Holdings’s EPS estimate is -0.08.
How many shares outstanding does Reviva Pharmaceuticals Holdings have?
Reviva Pharmaceuticals Holdings has 96,337,120 shares outstanding.
What happened to Reviva Pharmaceuticals Holdings’s price movement after its last earnings report?
Reviva Pharmaceuticals Holdings reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.095. Following the earnings report the stock price went down -7.407%.
Which hedge fund is a major shareholder of Reviva Pharmaceuticals Holdings?
Currently, no hedge funds are holding shares in RVPH
Reviva Pharmaceuticals Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.14 (869.81% Upside)
$5.14 (869.81% Upside)
Hedge Fund Trend
Decreased
By 684.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
44.48%
Trailing 12-Months
Company Description
Reviva Pharmaceuticals Holdings
Reviva Pharmaceuticals Holdings (RVPH) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate, Brilaroxazine, is aimed at treating schizophrenia and other neuropsychiatric disorders. Reviva Pharmaceuticals operates primarily in the pharmaceutical sector, leveraging its proprietary technologies to advance its pipeline of drug candidates through clinical development.
RVPH Stock 12 Month Forecast
Average Price Target
$5.14
▲(869.81% Upside)
Technical Analysis
Cel-Sci
―
Plus Therapeutics
―
XBiotech
―
Prelude Therapeutics
―
Coeptis Therapeutics Holdings
―
Ownership Overview
1.84%
Insiders
1.92% Mutual Funds
0.53% Other Institutional Investors
94.32% Public Companies and
Individual Investors